USPTO Grants New Inhaler Patent
Hovione recently announced that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than 3 years after the patent was filed and after just one Office Action – unusual speed for an inhaler application.
Hovione has designed this inhaler to have just two operating components, thereby achieving significant cost savings and giving the patient unprecedented ease of use. In use, the patient just needs two steps before inhaling. In terms of delivery performance, lung fractions in excess of 70% have been achieved. This makes this inhaler highly suited for inhalation applications in which minimal training of patients is desirable and has the versatility to treat most pulmonary diseases, including asthma, COPD, as well as infection, which typically requires very large doses.
XCaps follows on the heels of another successful Hovione DPI, TwinCaps, which was developed for the delivery of the anti-viral drug, laninamivir, to treat influenza and is now approved in Japan and marketed by licensee Daiichi-Sankyo as part of their Inavir product. Hovione inhalers are offered for licensing, together with formulation and particle engineering services on a fee-for-service basis. The company has also developed a line of inhalation-grade APIs, including fluticasone, salmeterol, mometasone, and tiotropium.
“We give our customers an edge in speed of development because we are perhaps the only independent company developing DPIs with expertise in every aspect of the inhaled drug development process,”said Peter Villax, Vice-President and co-inventor of the device. “This patent grant in the US within 30 months of initial filing, underpins Hovione’s capabilities in innovation and intellectual property management, to successfully design, develop, and deliver innovative products.”
“The XCaps addresses a gap for a simple, easy-to-use, cost-effective, multiple-use, capsule-based inhalation device. This allows our business partners to take advantage of additional patent protection for their inhalation drug product and effective drug product life cycle management,” said Gonçalo Andrade, Business Development Manager.
Hovione is currently executing inhaled drug development projects for 5 pharmaceutical companies, involving API process development, particle engineering, formulation, and clinical supplies and is looking for partners willing to incorporate Hovione inhalers into their inhalation drug product development.
Hovione is an international company with over 50 years’ experience in API development and compliant manufacture. With four FDA-inspected sites in the US, China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. For more information, visit www.hovione.com.
Total Page Views: 1414
